Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma
Citations Over TimeTop 10% of 2011 papers
Abstract
Diffuse intrinsic pontine gliomas (DIPG) can not be cured with current treatment modalities. Targeted therapy in this disease would benefit from advanced technologies detecting relevant drugable mutations. Twenty patients with classic newly diagnosed DIPG underwent stereotactic biopsies and were analyzed for the presence of 983 different mutations in 115 oncogenes and tumor-suppressor genes using OncoMap, a mass spectrometric method of allele detection. Our results identified oncogenic mutations in TP53 (40%), PI3KCA (15%), and ATM/MPL (5%) while none were identified in a large number of other genes commonly mutated in malignant gliomas. The identification of oncogenic mutations in the PI3K pathway offers the potential of a therapeutic target at initial diagnosis in this devastating disease.
Related Papers
- → LncRNA LINC01094 contributes to glioma progression by modulating miR-224-5p/CHSY1 axis(2021)19 cited
- → MiRNA-93 functions as an oncogene in glioma by directly targeting RBL2.(2018)25 cited
- → Expression and functional implications of USP17 in glioma(2016)13 cited
- → CircRFX3 Up-regulates Its Host Gene RFX3 to Facilitate Tumorigenesis and Progression of Glioma(2022)6 cited
- → CPLX2 is a novel tumor suppressor and improves the prognosis in glioma(2023)